Monday, June 5, 2017

BRIEF-Celldex presents data from phase 2 study of glembatumumab vedotin

* Celldex presents promising overall survival data from phase 2 study of single-agent glembatumumab vedotin in patients with checkpoint-refractory metastatic melanoma

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)